QUT’s scientific and innovation credentials have been celebrated as part of the 2018 BIO International Convention, with the University signing three key industry agreements, including a major announcement for a promising pre-clinical anti-cancer drug candidate invented by the Cancer and Ageing Research Program (CARP).
QUT Professor and co-inventor of DKLS02, CARP’s Derek Richard said the drug candidate had the potential to be used to treat a range of different cancers, including solid tumour cancers such as lung cancer, advanced prostate cancer and melanoma.
“This drug candidate is a first in class inhibitor of hSSB1, which is a protein that senses genetic damage in cells. As cancer cells have 1000 fold more DNA damage events than normal cells, they cannot tolerate the loss of hSSB1. Our drug, DKLS02, makes the cancer’s genetic code collapse, which in turn kills the cancer cells,” Professor Richard said.
“The development of this drug candidate has been very exciting for the team at the Cancer and Ageing Research Program. The $5-million deal with CARP Pharmaceuticals will support the further development of DKLS02, including toxicology assessment.
“The funds were raised by Mantle Group CEO, Godfrey Mantle, and we are extremely proud that it will allow the work that is required to progress the drug, to happen in Queensland,” he said.
As part of the 2018 BIO International Convention, QUT also signed agreements with Elo Life Systems and with Philips Research.